Lataa...
5PSQ-080 Effectiveness and security of alemtuzumab in relapsing-remitting multiple sclerosis
BACKGROUND: Alemtuzumab is a humanised monoclonal antibody that selectively targets CD52, resulting in depletion and subsequent distinct repopulation of circulating T and B lymphocytes. PURPOSE: To evaluate the effectiveness and security of alemtuzumab in patients diagnosed with relapsing-remitting...
Tallennettuna:
| Julkaisussa: | Eur J Hosp Pharm |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BMJ Group
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7535589/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.434 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|